Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.

[1]  C. Higano.  Management of bone loss in men with prostate cancer. , 2003, The Journal of urology.

[2]  Matthew R. Smith.  Osteoporosis during androgen deprivation therapy for prostate cancer. , 2002, Urology.

[3]  S. Cerutti,et al.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. , 2002, The Journal of urology.

[4]  A. Furuta,et al.  Incidence of bone fracture in patients receiving luteinizing hormone‐releasing hormone agonists for prostate cancer , 2000, BJU international.

[5]  John T. Wei,et al.  Androgen deprivation therapy for prostate cancer results in significant loss of bone density. , 1999, Urology.

[6]  R A Boileau,et al.  The physical activity scale for the elderly (PASE): evidence for validity. , 1999, Journal of clinical epidemiology.

[7]  J. Sibilia,et al.  Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. , 1999, The Journal of urology.

[8]  T. Diamond,et al.  The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma , 1998, Cancer.

[9]  P. Ross.  Risk factors for osteoporotic fracture. , 1998, Endocrinology and metabolism clinics of North America.

[10]  E. Orwoll.  Osteoporosis in men. , 1998, Endocrinology and metabolism clinics of North America.

[11]  A Hofman,et al.  Risk factors for increased bone loss in an elderly population: the Rotterdam Study. , 1998, American journal of epidemiology.

[12]  E. Keller,et al.  Immunologic aspects of osteoporosis. , 1997, Developmental and comparative immunology.

[13]  H. Daniell.  Osteoporosis after orchiectomy for prostate cancer. , 1997, The Journal of urology.

[14]  S. Graham,et al.  Bone fractures associated with luteinizing hormone‐releasing hormone agonists used in the treatment of prostate carcinoma , 1997, Cancer.

[15]  J. H. Romeo,et al.  Osteoporosis in men: a review. , 1996, The Nursing clinics of North America.

[16]  J. Eisman,et al.  Risk Factors for Osteoporotic Fractures in Elderly Men , 1996 .

[17]  K. Carlström,et al.  Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens , 1995, Calcified Tissue International.

[18]  W. O'Fallon,et al.  Long‐term fracture prediction by bone mineral assessed at different skeletal sites , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  R. Rees,et al.  Regulation of matrix metalloproteinases - their role in tumor invasion and metastasis. , 1993, International journal of oncology.

[20]  A. Jette,et al.  The Physical Activity Scale for the Elderly (PASE): development and evaluation. , 1993, Journal of clinical epidemiology.

[21]  D. Ferguson,et al.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer. , 2000, The Journal of urology.

[22]  D W Bates,et al.  Can comorbidity be measured by questionnaire rather than medical record review? , 1996, Medical care.

[23]  John P. Bilezikian,et al.  Principles of Bone Biology , 1996 .

[24]  L. Liotta,et al.  Tumor cell interactions with the extracellular matrix during invasion and metastasis. , 1993, Annual review of cell biology.

[25]  E. Orwoll,et al.  The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. , 1990, Annals of internal medicine.

[26]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.